1nhaler raises £2.2M to ready cardboard inhaler for clinical trials
What's the deal? 1nhalerDealroom has a profile for this one. Try Dealroom →, an Edinburgh-based drug delivery device developer, has raised £2.2 million in funding. The round was led by ArchangelsDealroom has a profile for this one. Try Dealroom →, with participation from Scottish Enterprise and BBB Investments.
What's the endgame? 1nhaler makes a single-dose dry powder inhaler (DPI) built predominantly from cardboard, in the shape and size of a credit card. It unfolds into a three-dimensional inhaler via a patented membrane-based system, offering a lower-carbon, propellant-free alternative to plastic inhalers.
The platform is designed to deliver medicines for conditions including asthma, chronic obstructive pulmonary disease (COPD), influenza, epilepsy, depression, and Parkinson's.
Where the money goes: The funds will support late-stage development of lead product 1nhaler Salbutamol and transfer the product into contract manufacturing for clinical trial material. The company also plans a small clinical trial aimed at a late-2027 regulatory filing, alongside business development discussions.
Why now? The raise moves 1nhaler toward regulatory readiness, a key milestone before any marketing authorisation. It fits a wider industry push to cut inhalers' environmental impact, though major manufacturers are also pursuing lower-emission propellants for conventional pressurised devices.
1nhaler was founded by Don Smith and chief executive officer Lisa McMyn.
The signal: Sustainability is becoming a competitive axis in respiratory medicine, where plastic and propellant-heavy inhalers carry a sizeable carbon footprint. Backing from Archangels and Scottish Enterprise signals continued investor appetite for Scottish medtech tackling that gap — if the clinical and manufacturing work lands on schedule.
Read more: finsmes.com
Image credit: Generated with Gemini
